Molecular and Immunological Department, Bio-therapeutic Department Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, 100853, China.
J Hematol Oncol. 2019 Nov 29;12(1):128. doi: 10.1186/s13045-019-0813-7.
The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with "OR", "AND" and "NOT" Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.
美国食品和药物管理局（FDA）批准两种嵌合抗原受体修饰的 T 细胞用于治疗血液系统恶性肿瘤，这是免疫治疗的一个里程碑；然而，CAR-T 细胞的应用受到抗原逃逸和靶内、脱靶毒性的限制。因此，选择合适的靶点，并结合多抗原靶向 CAR-T 细胞与“或”、“与”和“非”布尔逻辑门，可能是一种潜在有效的策略。我们总结了 CAR-T 细胞目前的局限性，以及逻辑门控 CAR-T 细胞在抗肿瘤治疗中的疗效和安全性。这篇综述将有助于探索更优化的策略来扩大 CAR-T 细胞的治疗窗口。
Zotero 插件